ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,962 GBX | -0.56% |
|
+2.24% | +3.28% |
| 09:40am | AstraZeneca's hails Imfinzi survival data on cancer form | AN |
| 08:30am | AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
137.3
USD
Average target price
162.5
USD
Spread / Average Target
+18.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.28% | 213B | |
| +28.79% | 676B | |
| +24.47% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +0.72% | 207B | |
| -8.75% | 199B | |
| -10.00% | 147B | |
| -7.82% | 142B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : Confirms 'Collaborative Meeting' with EU on COVID-19 Vaccine Delivery Dispute
